论文部分内容阅读
目的测定恶性肿瘤患者血清中胱抑素C(cystatinC)水平,探讨其临床价值。方法应用颗粒增强散射免疫比浊法(PENIA)测定155例恶性肿瘤患者血清中cystatinC浓度,同时测定血清中尿素氮、肌酐、β2-微球蛋白。结果恶性肿瘤患者血清中cystatinC较健康对照组显著增高(P<0.01),差异有统计学意义;恶性肿瘤患者血清中CystatinC浓度与肌酐、β2-微球蛋白水平呈正相关,并具有统计学意义。结论测定恶性肿瘤患者血清中cystatinC浓度能早期发现潜在的肾功能损害和肾功能改变,灵敏度高于其他肾功能指标。
Objective To determine the level of serum cystatin C in patients with malignant tumor and to explore its clinical value. Methods Serum levels of cystatin C in 155 patients with malignant tumor were measured by particle-enhanced immuno-turbidimetry (PENIA), and serum urea nitrogen, creatinine and β2-microglobulin were measured simultaneously. Results Serum cystatin C in patients with malignant tumors was significantly higher than that in healthy controls (P <0.01), and the difference was statistically significant. Serum levels of Cystatin C were positively correlated with creatinine and β2-microglobulin in patients with malignant tumors, and had statistical significance. Conclusions The determination of cystatin C in the serum of patients with malignant tumors can detect potential renal damage and renal function changes earlier, with higher sensitivity than other renal function indexes.